|
Patent landscape, scope, and claims: |
US Patent 6,320,074: Scope, Claim Strength, and Competitive Patent Landscape
US Patent 6,320,074 is a broad chemical and functional patent family centered on Retinoid X Receptor (RXR) selective agonism over Retinoic Acid Receptors (RAR). The claims build coverage in three layers: (i) a wide Markush-style compound genus with extensive substitution freedom, (ii) explicit functional recitations tied to RXR selectivity and utility, and (iii) downstream product and method claims (pharmaceutical compositions, in vivo/in vitro methods, receptor binding, receptor purification, and “determining presence” assays).
The claim set you provided also contains internal redundancy: claim 1 establishes the genus; claim 2 narrows by RXR selectivity; claims 3 to 9 and 4 to 8 and 5 to 6 to 7 are enumerated examples. The remaining claims (10 to 41) extend the genus to formulation and multiple therapeutic and diagnostic embodiments.
What is the claim structure and what exactly is claimed?
Claim 1: Broad Markush genus for RXR ligands
Claim 1 recites “A compound having the formula” with multi-variable substitution parameters. The scope is defined by:
-
Core substituent handles
- R1, R2 independently: hydrogen or lower alkyl or acyl with 1–4 carbons
- Y: C, O, S, N, CHOH, CO, SO, SO2 or a pharmaceutically acceptable salt
- R3: hydrogen or lower alkyl (1–4) where Y is C or N
- R4: hydrogen or lower alkyl (1–4) where Y is C, but R4 does not exist if Y is N
- Exclusion logic:
- neither R3 nor R4 exist if Y is S, O, CHOH, CO, SO, or SO2
-
Substituent pair logic
- R′ and R″: H, lower alkyl or acyl (1–4), OH, alkoxy (1–4), thiol or thioether, amino, or forms fused functionalities “taken together”
- The “taken together” clause creates additional ring/linkage motifs:
- oxo (keto), methano, thioketo
- HO—N═, NC—N═
- (R7R8)N—N═
- R17O—N═, R17N═
- epoxy
- cyclopropyl
- cycloalkyl group
- and allows substitution on epoxy/cyclopropyl/cycloalkyl by lower alkyl (1–4) or halogen
-
Additional ring constraints
- R′″ and R″″: H, halogen, lower alkyl or acyl (1–4), alkyl amino, or form a cycloalkyl group 3–10 carbons, substituted by lower alkyl (1–4) or halogen
-
R5 and R6/R10/R11/R12/R13: high substitution breadth
- R5: hydrogen or lower alkyl (1–4), halogen, nitro, OR7, SR7, NR7R8, R6, R10, R11, R12, R13 (each independently), or (CF2)nCF3
- Existence depending on Z-type origin
- R6, R10, R11, R12, R13 each independently:
- if originating Z is C: H, lower alkyl (1–4), halogen, nitro, OR7, SR7, NR7R8, or (CF2)nCF3
- if originating Z is N: only H or lower alkyl (1–4)
- plus: “where one of R6, R10, R11, R12 or R13 is X”
-
“X” is the acidic/ionizable handle
- R9: α-lower alkyl (1–4), phenyl/aromatic alkyl, or substituted carboxyphenyl/hydroxyphenyl/halophenyl/fluorophenyl/iodophenyl with q = 2–4
- X: COOH, tetrazole, PO3H, SO3H, CHO, CH2OH, CONH2, COSH, COOR9, COSR9, CONHR9, or COOW (W is pharmaceutically acceptable salt)
- “X can originate from any C or N on the ring,” subject to further constraints in later dependent claim set
-
Z, Z′, Z″, Z′″, Z″″ ring heteroatom pattern
- each independently: O, N, or pharmaceutically acceptable salt; the rest are C
- global constraints:
- “all Z’s may represent C in the second structure but one of Z/Z′/Z″/Z′″/Z″″ is not O or S if attached by a double bond to another such Z or if attached to another such Z which is O or S”
- “not N if attached by a single bond to another such Z which is N”
- and “not O or S in any six-membered rings containing them”
-
Saturation state and optional double bonds
- n = 0–3
- “dashed lines in the fourth structure depict optional double bonds”
Net effect: Claim 1 covers a chemically large genus driven by (i) variable heteroatom positions (Y, Z-positions), (ii) interchangeable “X” acidic/ionizable group types, (iii) multiple allowed substituents and cycloalkyl/epoxy motifs, and (iv) RXR-selective functional language later in dependent claims.
Claim 2: Functional narrowing to RXR selectivity
Claim 2 depends on claim 1 and adds a potency/selectivity requirement:
- “selectively activates Retinoid X Receptors in preference to Retinoic Acid Receptors.”
This language constrains the genus to compounds that produce a functional preference for RXR over RAR in the claimed activity.
Claims 3 to 9: Enumerated exemplars
Claims 3 to 9 list specific molecules, including:
- multiple benzoic acid derivatives bearing a substituted tetrahydronaphthyl (pentamethyl-tetrahydro-2-naphthyl) carbonyl and eth(en)yl or cyclopropyl/ethenyl linkages
- a tetrazole substituted version
- multiple pyridine-5-carboxylic acid derivatives (including ethyl ester forms)
- oxime derivatives (butyloxime, propyloxime, cyanoimine, allyloxime, aminoethyl oxime, methyloxime, etc.)
These exemplars matter for two reasons:
1) they anchor the chemistry in a particular scaffold family (the “pentamethyl tetrahydro-naphthyl” substitution pattern); and
2) they may help distinguish prior art if those scaffolds are novel in combination with the functional selectivity.
Claims 10 and 11: Pharmaceutical compositions
- Claim 10: composition containing “one or more ligands which modulate a process selectively mediated by RXR in preference to RAR”
- Claim 11: composition containing “one or more compounds of claim 1”
This is a standard formulation extension: broad composition coverage with the same functional mechanism tied to RXR preference.
Claims 12 to 14: Method of modulation
- Claim 12: modulating a process selectively mediated by RXR by conducting the process in the presence of a ligand that selectively activates RXR over RAR
- Claim 13: includes a quantitative modifier, “at least five-fold more potent an activator of RXR than of RAR”
- Claim 14: again broadly recites modulation by at least one RXR-preferential ligand
Claims 15 to 21: Additional methods tethered to the formula
Claim 15 is a full reprint of a compound formula (similar to claim 1 but with more specific constraints) and then claims:
- Claim 16: RXR subtypes (alpha, beta, gamma)
- Claim 17-20: specific utility areas (lipid metabolism, skin-related processes, autoimmune diseases, fatty acid metabolism, malignant cell development, premalignant lesions, programmed cell death; enhancement/inhibition of apoptosis; cellular growth and differentiation; limb morphogenesis)
- Claim 21: method comprising conducting a process in the presence of at least one compound “as set forth in claim 3” (i.e., the enumerated molecules)
Claims 22 to 26: Treatment and pharmacokinetic/pharmacodynamic claims
- Claim 22: administer “amount effective” to modulate RXR-mediated process
- Claim 23: administer effective amount of compounds of claim 1
- Claim 24: treat mammalian subject requiring RXR therapy
- Claim 25: treat using compounds as in claim 1
- Claim 26: increase plasma HDL concentrations
These are strong commercial hooks because they are closer to clinical endpoints and product positioning.
Claims 27 to 28 and 40 to 41: Receptor binding and purification
- Claim 27: determining presence of unknown receptors by combining sample with the compound and testing binding
- Claim 28: purifying RXR by binding and separating bound complex
- Claims 40 and 41 mirror these with claim 29-based compounds
These create additional enforcement paths against assay and research workflows.
How broad is the chemical scope in practical terms?
Scope drivers
The patent’s breadth stems from three “degrees of freedom” that expand combinatorial coverage:
1) Core heteroatom variability
- Y has multiple values (C, O, S, N, CHOH, CO, SO, SO2, salts).
- Z-positions allow O or N (or salts), with C as default and explicit ring-constraint rules.
2) Ionizable group “X” replacement
- X spans acids, sulfonic acids, tetrazoles, alcohol/aldehyde/amides, thioacids, thioesters/esters, and salts.
- X can originate from any C or N on the ring, subject to positional constraints in later claims (claim 29).
3) Substituent “swapping” with conditional availability
- R1/R2 allow small alkyl/acyl variation.
- R′/R″ allow multiple polar functionalities and a broad “taken together” motif class including epoxy and rings.
- R5 and several R6/R10/R11/R12/R13 positions allow a broad menu including halo, nitro, OR7/SR7/NR7R8, and (CF2)nCF3.
Scope limits and structural “gates”
The claim includes several constraints that reduce but do not eliminate risk of overreach:
- R3/R4 only exist under certain Y conditions
- Z-atom patterns have bonding constraints (double bond attachment restrictions; ring-position restrictions for O/S/N adjacency rules)
- Cycloalkyl group size is limited: 3–10 carbons
- Many substituents are lower-alkyl limited to 1–4 (except R7/R8 at 1–6, R17 at 1–8)
Commercial conclusion: Even with gates, the genus is wide enough to capture numerous medicinal-chemistry variants as long as the scaffold maintains the core ring topology and RXR-preferential pharmacology required by dependent claims.
Where does claim enforceability likely concentrate?
1) RXR selectivity language (claims 2, 12-14, 30)
The selectivity requirement appears multiple times:
- claim 2: preference of RXR over RAR
- claim 12: selective RXR activation over RAR for modulation
- claim 13: “at least five-fold more potent”
- claim 30 and claim 31-like constructs for compound of claim 29
Actionable implication for freedom-to-operate (FTO):
- Compounds outside selectivity could be non-infringing for the dependent claims, but independent compound coverage still exists for claim 1 unless the dependent selectivity is made a limitation in the claim being asserted.
- In practice, litigated claim sets often hinge on the functional limitation, so RXR vs RAR activity ratios matter.
2) Enumerated examples (claims 3-9, and claim 21)
Example listing creates:
- a roadmap of the chemical space the patent owner expects to defend
- a narrower set for enforcement via “compound as set forth” type claims
3) Utility claims for HDL and programmed cell death
- Claim 26 (HDL increase) is a specific commercial target.
- Claims 17-20, 34-35 frame apoptosis modulation and oncology-like endpoints. These may overlap with broad RXR biology, raising the probability of “use” challenge rather than chemical originality challenge.
What is claim 29 (and the later claim set) doing differently?
The later claim block (claims 29 onward) recites a very similar formula but includes explicit positional restrictions on X generation:
- “X can originate from any C on the ring, provided however, that X cannot be COOH, CHO, CH2OH, CONH2, COOR9, or COOW where W is a pharmaceutically acceptable salt when X originates from a C in the 2 or 6 position on the ring.”
This is a meaningful constraint relative to claim 1’s broader “any C or N” origin logic, and it narrows the positional acceptability of certain groups.
Claim 29 then is followed by:
- claim 30: RXR selectivity preference
- claim 31: composition administering compound(s) of claim 29
- claims 32-41: expanded methods tied to the claim 29 formula and its compounds
Net effect: claim 29 creates a second, more constrained genus within the same overall scaffold family that can:
- preserve coverage against prior art targeting the prohibited positional pattern, and
- create a fallback position if claim 1’s broader language is challenged.
Competitive patent landscape: how to map the risk
Given only the claim text and no publication dates, assignee names, prosecution history, or cited references, a complete, competitor-by-competitor landscape cannot be produced accurately. What can be done from the claim scope alone is a risk map of what types of competitor patents are most likely to overlap with this one.
Overlap zones that matter for RXR-selective programs
1) RXR agonist chemical genera with acidic ionizable groups
- Overlap risk rises for compounds containing: carboxylic acids, tetrazoles, sulfonic acids, phosphate-like groups, and ester/salt forms on similar scaffolds.
2) Carboxylate/tetrazole “X” replacements
- Any competitor that substitutes X with tetrazole or carboxylate/salt equivalents in comparable ring systems faces risk because the genus explicitly includes those classes.
3) RXR vs RAR selectivity claims
- Competitors that claim RXR selectivity “preference” language (including potency ratio thresholds like 5-fold) tend to collide with dependent claims.
4) Formulations and route of administration
- Claim 10 and 31 cover compositions in pharmaceutically acceptable vehicles for enteral, parenteral, or topical administration.
- Competitors that sell RXR agonists in standard formulations have higher risk of at-issue infringement if the active ingredient falls inside the chemical genus.
5) HDL increase
- Programs marketed around dyslipidemia or HDL increase face an additional claim pathway (claim 26).
6) Assays: receptor binding and purification
- Research tool patents that use ligands as binders or affinity reagents create risk for claims like 27/28/40/41.
Practical infringement logic by claim tier
Tier A: Direct compound coverage
- Claim 1: direct compound coverage for the broad genus
- Claim 29: similar but narrower genus with a positional restriction on certain X types
If a competitor’s active ingredient falls into the literal genus, Tier A is the central risk.
Tier B: Dependent RXR-preference enforcement
- Claims 2, 12-14, 30, 33-39: add functional constraints
- If a competitor’s compound is RXR agonist but not RXR-selective over RAR, it may avoid dependent claim infringement.
Tier C: End-use and composition hooks
- Claims 10, 11, 31: formulations
- Claims 22-26, 37-39: treatment and HDL/biological outcomes
Even if chemical coverage is contested, these claims can be asserted where active ingredient and biological use are aligned.
Key Takeaways
- US 6,320,074 claims a large RXR-selective agonist chemical genus with extensive Markush variability over heteroatoms (Y, Z positions), substitution patterns (R′/R″, cycloalkyl size 3–10), and especially the ionizable group “X” (COOH, tetrazole, SO3H, PO3H, aldehyde/alcohol/amide variants, thioacid/ester variants, and salts).
- The patent’s enforcement leverage increases in dependent claims that require RXR activation preference over RAR, including a quantified “at least five-fold” potency differential (claim 13).
- The claim set also expands to pharmaceutical compositions, multiple treatment/utilities (including apoptosis modulation and HDL increase), and receptor binding/purification assays.
- A two-track chemical scope exists: claim 1 provides broader “X origin” freedom; claim 29 narrows the permissible X types at specific ring positions (2 or 6), creating a fallback genus for enforcement.
- A complete competitor-by-competitor landscape cannot be derived from claim text alone; the most relevant overlap areas are competitors’ RXR-selective agonists that include acid/tetrazole/sulfonate/phosphate-like ionizable groups and claim RXR-preference activity.
FAQs
1) What is the main novelty driver in US 6,320,074?
The main driver is a wide scaffold genus paired with an explicit functional limitation: selective RXR activation over RAR, plus broad chemical coverage of ionizable “X” groups and substituted ring positions.
2) Does the patent cover only specific named compounds?
No. Named compounds (claims 3-9) are exemplars, but the core coverage is the broad genus in claim 1 (and a narrower follow-on genus in claim 29).
3) How does “X” affect infringement risk?
“X” defines the ionizable functionality and includes many classes (carboxylic acid, tetrazole, sulfonic acid, phosphonic acid, aldehyde/alcohol/amides, thio variants, and salts). Competitor actives with equivalent “X” chemistry on the covered scaffold increase risk.
4) Are assays and receptor purification covered?
Yes. Claims like 27-28 and 40-41 cover determining presence of receptors by binding and purifying RXR via ligand binding and separation.
5) What is the practical impact of the “five-fold” requirement?
It appears in claim 13 as a potency/selectivity threshold. Compounds may still fall under broader chemical coverage (claim 1) but will be harder to fit into dependent claims requiring that quantitative RXR-over-RAR differential.
References
[1] US Patent 6,320,074 (claims as provided in user input).
More… ↓
⤷ Start Trial
|
